期刊
ACTAS DERMO-SIFILIOGRAFICAS
卷 103, 期 7, 页码 579-590出版社
ELSEVIER ESPANA
DOI: 10.1016/j.ad.2011.08.009
关键词
Melanoma; Therapeutic targets; Molecular targets; BRAF; C-kit; Anti CTLA-4
类别
Research into molecular targets for drug development in melanoma is starting to bear fruit. Of the drugs tested to date in patients with metastatic melanoma, those that have yielded the best results are V600E BRAF inhibitors in melanomas carrying the V600E mutation; c-kit tyrosine kinase activity inhibitors in melanomas carrying c-kit mutations; and anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibodies, which block the mechanisms involved in immune tolerance. Many problems have yet to be resolved in these areas, however, such as the rapid development of resistance to BRAF and c-kit inhibitors and the lack of biomarkers to predict treatment response in the case of CTLA-4 blockers. We review the results of targeted therapy with these and other drugs in metastatic melanoma and discuss what the future holds for this field. (C) 2011 Elsevier Espana, S.L. and AEDV. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据